{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:14:20Z","timestamp":1788884060389,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10620-018-5448-y","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T10:02:33Z","timestamp":1548410553000},"page":"1419-1431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-5736","authenticated-orcid":false,"given":"Frederik","family":"Nevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Lisboa","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minneke J.","family":"Coenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiguo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mendizabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeli Xochiquetzal","family":"Ortiz-Olvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio D.","family":"Vorobioff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"5448_CR1","doi-asserted-by":"publisher","first-page":"e000025","DOI":"10.1136\/bmjgast-2014-000025","volume":"2","author":"L Scalone","year":"2015","unstructured":"Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol. 2015;2:e000025.","journal-title":"BMJ Open Gastroenterol"},{"key":"5448_CR2","first-page":"661","volume":"7","author":"GW Neff","year":"2011","unstructured":"Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y). 2011;7:661\u2013671.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"5448_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","volume":"49","author":"S Scaglione","year":"2015","unstructured":"Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690\u2013696.","journal-title":"J Clin Gastroenterol"},{"key":"5448_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u2013171.","journal-title":"Lancet"},{"key":"5448_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000317248","volume":"16","author":"WA Zato\u0144ski","year":"2010","unstructured":"Zato\u0144ski WA, Sulkowska U, Ma\u0144czuk M, et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res. 2010;16:193\u2013201.","journal-title":"Eur Addict Res"},{"key":"5448_CR6","doi-asserted-by":"crossref","unstructured":"LaBrecque D, Khan AG, Sarin SK, LeMair AW. Esophageal Varices. World Gastroenterology Organisation Global Guidelines; 2014.","DOI":"10.1097\/MCG.0000000000000116"},{"key":"5448_CR7","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.3748\/wjg.v19.i31.5035","volume":"19","author":"E Biecker","year":"2013","unstructured":"Biecker E. Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol. 2013;19:5035\u20135050.","journal-title":"World J Gastroenterol"},{"key":"5448_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4253\/wjge.v6.i5.168","volume":"6","author":"M Triantafyllou","year":"2014","unstructured":"Triantafyllou M, Stanley AJ. Update on gastric varices. World J Gastrointest Endosc. 2014;6:168\u2013175.","journal-title":"World J Gastrointest Endosc"},{"key":"5448_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.4103\/1735-1995.172990","volume":"20","author":"ZA Wani","year":"2015","unstructured":"Wani ZA, Bhat RA, Bhadoria AS, Maiwall R, Choudhury A. Gastric varices: classification, endoscopic and ultrasonographic management. J Res Med Sci. 2015;20:1200\u20131207.","journal-title":"J Res Med Sci"},{"key":"5448_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/0016-5085(81)90144-X","volume":"80","author":"DY Graham","year":"1981","unstructured":"Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800\u2013899.","journal-title":"Gastroenterology"},{"key":"5448_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000456594","volume":"35","author":"F Nevens","year":"2017","unstructured":"Nevens F. Novel approaches to reducing the risk of variceal hemorrhage. Dig Dis. 2017;35:397\u2013401.","journal-title":"Dig Dis"},{"key":"5448_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"Franchis de","year":"2015","unstructured":"de Franchis. On behalf of the Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743\u2013752.","journal-title":"J Hepatol"},{"key":"5448_CR13","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","volume":"24","author":"JC Garcia-Pag\u00e1n","year":"2010","unstructured":"Garcia-Pag\u00e1n JC, Caca K, Bureau C, et al. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) cooperative study group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;24:2370\u20132379.","journal-title":"N Engl J Med"},{"key":"5448_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.dld.2013.12.010","volume":"46","author":"V Jairath","year":"2014","unstructured":"Jairath V, Rehal S, Logan R, et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis. 2014;46:419\u2013426.","journal-title":"Dig Liver Dis"},{"key":"5448_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/gastro\/gox009","volume":"5","author":"T Bucsics","year":"2017","unstructured":"Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep. 2017;5:127\u2013137.","journal-title":"Gastroenterol Rep"},{"key":"5448_CR16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jhep.2011.03.012","volume":"55","author":"F Salerno","year":"2011","unstructured":"Salerno F, Cazzaniga M, Merli M, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55:1241\u20131248.","journal-title":"J Hepatol"},{"key":"5448_CR17","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310\u20131318.","journal-title":"Gut"},{"key":"5448_CR18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.01340406","volume":"1","author":"HM Wadei","year":"2006","unstructured":"Wadei HM, Mai ML, Ashan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066\u20131079.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5448_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gin\u00e8s","year":"1993","unstructured":"Gin\u00e8s A, Escorsell A, Gin\u00e8s P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229\u2013236.","journal-title":"Gastroenterology"},{"key":"5448_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/apt.13912","volume":"45","author":"FJ Gifford","year":"2017","unstructured":"Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45:593\u2013603.","journal-title":"Aliment Pharmacol Ther"},{"key":"5448_CR21","unstructured":"Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence: Introductory Document. Oxford Centre for Evidence-Based Medicine. Available at: \n                    https:\/\/www.cebm.net\/wp-content\/uploads\/2014\/06\/CEBM-Levels-of-Evidence-Introduction-2.1.pdf\n                    \n                  . Accessed August 22, 2018."},{"key":"5448_CR22","unstructured":"OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based Medicine\u2014Levels of Evidence (March 2009). Available at: \n                    https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/\n                    \n                  . Accessed August 22, 2018."},{"key":"5448_CR23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","volume":"64","author":"D Tripathi","year":"2015","unstructured":"Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64:1680\u20131704.","journal-title":"Gut"},{"key":"5448_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310\u2013335.","journal-title":"Hepatology"},{"key":"5448_CR25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/hep.510290608","volume":"29","author":"B Bernard","year":"1999","unstructured":"Bernard B, Grang\u00e9 JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655\u20131661.","journal-title":"Hepatology"},{"key":"5448_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/jhep.2002.31354","volume":"35","author":"R Ba\u00f1ares","year":"2002","unstructured":"Ba\u00f1ares R, Albillos A, Rinc\u00f3n D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35:609\u2013615.","journal-title":"Hepatology"},{"key":"5448_CR27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/j.1365-2036.2012.05088.x","volume":"35","author":"M Wells","year":"2012","unstructured":"Wells M, Chande N, Adams P, Beaton M, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35:1267\u20131278.","journal-title":"Aliment Pharmacol Ther"},{"key":"5448_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3109\/00365529009095539","volume":"25","author":"C S\u00f6derlund","year":"1990","unstructured":"S\u00f6derlund C, Magnusson I, T\u00f6rngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 1990;25:622\u2013630.","journal-title":"Scand J Gastroenterol"},{"key":"5448_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00004836-198902000-00014","volume":"11","author":"JG Freeman","year":"1989","unstructured":"Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol. 1989;11:58\u201360.","journal-title":"J Clin Gastroenterol"},{"key":"5448_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hep.1840060121","volume":"6","author":"S Walker","year":"1986","unstructured":"Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology. 1986;6:112\u2013115.","journal-title":"Hepatology"},{"key":"5448_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(95)92708-5","volume":"346","author":"S Levacher","year":"1995","unstructured":"Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 1995;346:865\u2013868.","journal-title":"Lancet"},{"key":"5448_CR32","doi-asserted-by":"crossref","unstructured":"Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2003; Art. No: CD002147.","DOI":"10.1002\/14651858.CD002147"},{"key":"5448_CR33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/hep.27006","volume":"60","author":"YS Seo","year":"2014","unstructured":"Seo YS, Park SY, Kim JH, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60:954\u2013963.","journal-title":"Hepatology"},{"key":"5448_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ajg.2008.147","volume":"104","author":"S Abid","year":"2009","unstructured":"Abid S, Jafri W, Hamid S, et al. Terlipressin versus octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009;104:617\u2013623.","journal-title":"Am J Gastroenterol"},{"key":"5448_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1053\/gast.1996.v111.pm8898643","volume":"111","author":"F Feu","year":"1996","unstructured":"Feu F, RuizdelArbol L, Ba\u00f1ares R, Planas R, Bosch J. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology. 1996;111:1291\u20131299.","journal-title":"Gastroenterology"},{"key":"5448_CR36","first-page":"692","volume":"34","author":"S Walker","year":"1996","unstructured":"Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices\u2014final report of a placebo-controlled, double-blind study. Z Gastroenterol. 1996;34:692\u2013698.","journal-title":"Z Gastroenterol"},{"key":"5448_CR37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/BF00212982","volume":"72","author":"G Pedretti","year":"1994","unstructured":"Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig. 1994;72:653\u2013659.","journal-title":"Clin Investig"},{"key":"5448_CR38","first-page":"61","volume":"18","author":"C Silvain","year":"1993","unstructured":"Silvain C, Carpentier S, Sautereau D, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology. 1993;18:61\u201365.","journal-title":"Hepatology"},{"key":"5448_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1590\/S0004-28032010000200017","volume":"47","author":"PL Bittencourt","year":"2010","unstructured":"Bittencourt PL, Farias AQ, Strauss E, et al. Pannel of the 1st Brazilian Consensus of Variceal Bleeding, Brazilian Society of Hepatology. Variceal bleeding: consensus meeting report from the Brazilian Society of Hepatology. Arq Gastroenterol. 2010;47:202\u2013216.","journal-title":"Arq Gastroenterol"},{"key":"5448_CR40","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s12325-008-0118-7","volume":"25","author":"A Krag","year":"2008","unstructured":"Krag A, Borup T, M\u00f8ller S, et al. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther. 2008;25:1105\u20131140.","journal-title":"Adv Ther"},{"key":"5448_CR41","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/hep.23893","volume":"52","author":"E Sola","year":"2010","unstructured":"Sola E, Lens S, Guevara M, et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010;52:1783\u20131790.","journal-title":"Hepatology"},{"key":"5448_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/MCG.0000000000000217","volume":"49","author":"SY Yim","year":"2015","unstructured":"Yim SY, Seo YS, Jung CH, et al. Risk factors for developing hyponatremia during terlipressin treatment: a retrospective analyses in variceal bleeding. J Clin Gastroenterol. 2015;49:607\u2013612.","journal-title":"J Clin Gastroenterol"},{"key":"5448_CR43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","volume":"60","author":"PS Ge","year":"2014","unstructured":"Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643\u2013653.","journal-title":"J Hepatol"},{"key":"5448_CR44","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1440-1746.2005.03902.x","volume":"20","author":"G Kalambokis","year":"2005","unstructured":"Kalambokis G, Economou M, Paraskevi K, et al. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. J Gastroenterol Hepatol. 2005;20:1075\u20131081.","journal-title":"J Gastroenterol Hepatol"},{"key":"5448_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1080\/003655202317316132","volume":"37","author":"HC Lin","year":"2002","unstructured":"Lin HC, Yang YY, Hou MC, et al. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. Scand J Gastroenterol. 2002;37:482\u2013487.","journal-title":"Scand J Gastroenterol"},{"key":"5448_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0168-8278(03)00322-2","volume":"39","author":"D Nidegger","year":"2003","unstructured":"Nidegger D, Ragot S, Berthel\u00e9my P, et al. Cirrhosis and bleeding: the need for very early management. J Hepatol. 2003;39:509\u2013514.","journal-title":"J Hepatol"},{"key":"5448_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0140-6736(97)05099-X","volume":"350","author":"A Avgerinos","year":"1997","unstructured":"Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABEVE) randomised trial. Lancet. 1997;350:1495\u20131499.","journal-title":"Lancet"},{"key":"5448_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM200101043440104","volume":"344","author":"P Cal\u00e8s","year":"2001","unstructured":"Cal\u00e8s P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med. 2001;344:23\u201328.","journal-title":"N Engl J Med"},{"key":"5448_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0168-8278(97)80428-X","volume":"26","author":"A Escorsell","year":"1997","unstructured":"Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol. 1997;26:621\u2013627.","journal-title":"J Hepatol"},{"key":"5448_CR50","unstructured":"ClinicalTrials.gov Identifier: NCT0269586, To assess safety and efficacy of bolus versus continuous infusion of terlipressin in acute variceal bleeding. Available at: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02695862\n                    \n                  ."},{"key":"5448_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1440-1746.1991.tb00892.x","volume":"6","author":"TT Chang","year":"1991","unstructured":"Chang TT, Lee FY, Tsai YT, et al. A randomized controlled study of low-dose and high-dose terlipressin in the control of acute oesophageal variceal haemorrhage. J Gastroenterol Hepatol. 1991;6:481\u2013484.","journal-title":"J Gastroenterol Hepatol"},{"key":"5448_CR52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jhep.2011.11.019","volume":"56","author":"Z Azam","year":"2012","unstructured":"Azam Z, Hamid S, Jafri W, et al. Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial. J Hepatol. 2012;56:819\u2013824.","journal-title":"J Hepatol"},{"key":"5448_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2012.08.020","volume":"58","author":"JC Garcia-Pag\u00e1n","year":"2013","unstructured":"Garcia-Pag\u00e1n JC, Di Pascoli M, Caca K, et al. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45\u201350.","journal-title":"J Hepatol"},{"key":"5448_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.gie.2010.09.043","volume":"73","author":"I Altraif","year":"2011","unstructured":"Altraif I, Handoo FA, Aljumah A, et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc. 2011;73:245\u2013250.","journal-title":"Gastrointest Endosc"},{"key":"5448_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/liv.13277","volume":"37","author":"F Brunner","year":"2017","unstructured":"Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Int. 2017;37:104\u2013115.","journal-title":"Liver Int"},{"key":"5448_CR56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.dld.2009.02.006","volume":"41","author":"L Cipolletta","year":"2009","unstructured":"Cipolletta L, Zambelli A, Bianco MA, et al. Acrylate glue injection for acutely bleeding oesophageal varices: a prospective cohort study. Dig Liver Dis. 2009;41:729\u2013734.","journal-title":"Dig Liver Dis"},{"key":"5448_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1055\/s-0034-1392600","volume":"3","author":"JP Ribeiro","year":"2015","unstructured":"Ribeiro JP, Matuguma SE, Cheng S, et al. Results of treatment of esophageal variceal hemorrhage with endoscopic injection of n-butyl-2-cyanoacrylate in patients with Child-Pugh class C cirrhosis. Endosc Int Open. 2015;3:584\u2013589.","journal-title":"Endosc Int Open"},{"key":"5448_CR58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.21907","volume":"46","author":"G Garcia-Tsao","year":"2007","unstructured":"Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922\u2013938.","journal-title":"Hepatology"},{"key":"5448_CR59","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/j.1572-0241.2002.05622.x","volume":"97","author":"SK Sarin","year":"2002","unstructured":"Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol. 2002;97:1010\u20131015.","journal-title":"Am J Gastroenterol"},{"key":"5448_CR60","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1053\/jhep.2001.24116","volume":"33","author":"GH Lo","year":"2001","unstructured":"Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology. 2001;33:1060\u20131064.","journal-title":"Hepatology"},{"key":"5448_CR61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1067\/mge.2000.104976","volume":"52","author":"YH Huang","year":"2000","unstructured":"Huang YH, Yeh HZ, Chen GH, et al. Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointest Endosc. 2000;52:160\u2013167.","journal-title":"Gastrointest Endosc"},{"key":"5448_CR62","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1067\/mge.2000.107911","volume":"52","author":"YT Lee","year":"2000","unstructured":"Lee YT, Chan FK, Ng EK, et al. EUS-guided injection of cyanoacrylate for bleeding gastric varices. Gastrointest Endosc. 2000;52:168\u2013174.","journal-title":"Gastrointest Endosc"},{"key":"5448_CR63","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1155\/2010\/276273","volume":"24","author":"J Al-Ali","year":"2010","unstructured":"Al-Ali J, Pawlowska M, Coss A, Svarta S, Byrne M, Enns R. Endoscopic management of gastric variceal bleeding with cyanoacrylate glue injection: safety and efficacy in a Canadian population. Can J Gastroenterol. 2010;24:593\u2013596.","journal-title":"Can J Gastroenterol"},{"key":"5448_CR64","doi-asserted-by":"crossref","unstructured":"R\u00edos Castellanos E, Seron P, Gisbert JP, Bonfill Cosp X. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015; Art. No.: CD010180.","DOI":"10.1002\/14651858.CD010180.pub2"},{"key":"5448_CR65","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0016-5085(98)00640-4","volume":"114","author":"TN Chau","year":"1998","unstructured":"Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. \u201cSalvage\u201d transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998;114:981\u2013987.","journal-title":"Gastroenterology"},{"key":"5448_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S0168-8278(01)00185-4","volume":"35","author":"D Azoulay","year":"2001","unstructured":"Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590\u2013597.","journal-title":"J Hepatol"},{"key":"5448_CR67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1055\/s-2007-966591","volume":"39","author":"GH Lo","year":"2007","unstructured":"Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39:679\u2013685.","journal-title":"Endoscopy"},{"key":"5448_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gin\u00e8s P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164\u2013176.","journal-title":"Hepatology"},{"key":"5448_CR69","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","volume":"62","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gin\u00e8s P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968\u2013974.","journal-title":"J Hepatol"},{"key":"5448_CR70","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jhep.2013.12.032","volume":"60","author":"E Rodriguez","year":"2014","unstructured":"Rodriguez E, Elia C, Sol\u00e0 E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60:955\u2013961.","journal-title":"J Hepatol"},{"key":"5448_CR71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","volume":"55","author":"TD Boyer","year":"2011","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315\u2013321.","journal-title":"J Hepatol"},{"key":"5448_CR72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.03.001","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397\u2013417.","journal-title":"J Hepatol"},{"key":"5448_CR73","first-page":"268","volume":"7","author":"M Garcovich","year":"2009","unstructured":"Garcovich M, Zocco MA, Gasbarrini A. Clinical use of albumin in hepatology. Blood Transfus. 2009;7:268\u2013277.","journal-title":"Blood Transfus"},{"key":"5448_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11255-010-9725-8","volume":"43","author":"M Dobre","year":"2011","unstructured":"Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2011;43:175\u2013184.","journal-title":"Int Urol Nephrol"},{"key":"5448_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/039139880903200303","volume":"32","author":"F Fabrizi","year":"2009","unstructured":"Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials. Int J Artif Organs. 2009;32:133\u2013140.","journal-title":"Int J Artif Organs"},{"key":"5448_CR76","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","volume":"150","author":"TD Boyer","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, et al. For REVERSE Study Investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579\u20131589.e2.","journal-title":"Gastroenterology"},{"key":"5448_CR77","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/apt.14052","volume":"45","author":"AJ Sanyal","year":"2017","unstructured":"Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin versus placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45:1390\u20131402.","journal-title":"Aliment Pharmacol Ther"},{"key":"5448_CR78","first-page":"CD005162","volume":"9","author":"LL Gluud","year":"2012","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9:CD005162.","journal-title":"Cochrane Database Syst Rev"},{"key":"5448_CR79","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Mart\u00edn-Llah\u00ed","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20131359.","journal-title":"Gastroenterology"},{"key":"5448_CR80","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830\u2013835. \n                    https:\/\/doi.org\/10.1186\/s40064-015-1625-z\n                    \n                  .","journal-title":"Dig Dis Sci"},{"key":"5448_CR81","first-page":"30","volume":"64","author":"O Goyal","year":"2016","unstructured":"Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial. J Assoc Phys India. 2016;64:30\u201335.","journal-title":"J Assoc Phys India"},{"key":"5448_CR82","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293\u20131298.","journal-title":"J Hepatol"},{"key":"5448_CR83","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","volume":"103","author":"P Sharma","year":"2008","unstructured":"Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689\u20131697.","journal-title":"Am J Gastroenterol"},{"key":"5448_CR84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin versus terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499\u2013505.","journal-title":"J Hepatol"},{"key":"5448_CR85","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.27709","volume":"62","author":"M Cavallin","year":"2015","unstructured":"Cavallin M, Kamath PS. Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62:567\u2013574.","journal-title":"Hepatology"},{"key":"5448_CR86","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep.28396","volume":"63","author":"M Cavallin","year":"2016","unstructured":"Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983\u2013992.","journal-title":"Hepatology"},{"key":"5448_CR87","doi-asserted-by":"publisher","first-page":"16041","DOI":"10.1038\/nrdp.2016.41","volume":"2","author":"V Arroyo","year":"2016","unstructured":"Arroyo V, Moreau R, Kamath PS, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2016;2:16041.","journal-title":"Nat Rev Dis Primers"},{"key":"5448_CR88","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.kint.2017.04.048","volume":"92","author":"A Davenport","year":"2017","unstructured":"Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: Where does hepatorenal syndrome fit? Kidney Int. 2017;92:1058\u20131070.","journal-title":"Kidney Int"},{"key":"5448_CR89","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0036-1583202","volume":"36","author":"V Arroyo","year":"2016","unstructured":"Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis. 2016;36:109\u2013116.","journal-title":"Semin Liver Dis"},{"key":"5448_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30208","author":"V Arora","year":"2018","unstructured":"Arora V, Maiwall R, Vijayaraghavan R, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2018;. \n                    https:\/\/doi.org\/10.1002\/hep.30208\n                    \n                  .","journal-title":"Hepatology"},{"key":"5448_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.035","author":"S Piano","year":"2018","unstructured":"Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2018.01.035\n                    \n                  .","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5448_CR92","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Mart\u00edn-Llah\u00ed","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20131359.","journal-title":"Gastroenterology"},{"key":"5448_CR93","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","volume":"14","author":"C Alessandria","year":"2002","unstructured":"Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363\u20131368.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5448-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:19:37Z","timestamp":1579893577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5448-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5448"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5448-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Frederik Nevens has received a consultancy grant from Ferring. Manuel Mendizabal has received payments for lectures from Bristol-Myers Squibb, AbbVie, Gilead, Ferring and Bayer; honoraria for consulting from Ferring and Gilead. Paolo Angeli declares the following: 2014\u20132018: Sequana Medical AG Advisory Board; 2016\u20132018: Biovie Advisory Board and patent application; 2016 Gilead (Italy): Advisory board and grant; 2014 Bhering: travel grant; 2016 Kedrion: speaker invitation. Paulo Lisboa Bittencourt, Minneke J Coenraad, Huiguo Ding, Ming-Chih Hou, Pierre-Fran\u00e7ois Laterre, Nayeli Xochiquetzal Ortiz-Olvera, Julio D. Vorobioff, Wenhong Zhang declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}